Gender-Affirming Hormone Therapy for Transgender Females

Gender-Affirming Hormone Therapy for Transgender Females

The provision of hormone therapy, both estrogens and antiandrogens, to adult transgender females is well within the scope of practice of the obstetrician gynecologist. The goal is to induce feminizing changes and suppress previously developed masculinization. Estrogens in sufficient doses will usual...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical obstetrics and gynecology 2018-12, Vol.61 (4), p.705-721
1. Verfasser: RANDOLPH, JOHN F
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 721
container_issue 4
container_start_page 705
container_title Clinical obstetrics and gynecology
container_volume 61
creator RANDOLPH, JOHN F
description The provision of hormone therapy, both estrogens and antiandrogens, to adult transgender females is well within the scope of practice of the obstetrician gynecologist. The goal is to induce feminizing changes and suppress previously developed masculinization. Estrogens in sufficient doses will usually achieve both goals with augmentation by antiandrogens. The primary short-term risk of estrogens is thrombosis, but long-term risk in transgender females is unclear. Optimal care requires pretreatment education and assessment, individualized dosing, ongoing routine monitoring, and standard breast and prostate cancer screening.
doi_str_mv 10.1097/GRF.0000000000000396
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2112610380</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2112610380</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3566-2d159df20f6169d96abea2bf8d648af554a445b819c196b93afbe84e6c9e3cfc3</originalsourceid><addsrcrecordid>eNp9kE1Lw0AQhhdRbK3-A5EcvaTud7PHUmwrFASp52WzmW2jm6TuNpT--0ZbRTw4l4Hhed-BB6FbgocEq9HD7GU6xL-HKXmG-kQwmgpB8Tnqd0eVKopJD13F-IYx4WJELlGPYSokZbiPshnUBYR07FwZqrJeJfMmVE0NyXINwWz2iWtCsgymjqsvMplCZTzEa3ThjI9wc9oD9Dp9XE7m6eJ59jQZL1LLhJQpLYhQhaPYSSJVoaTJwdDcZYXkmXFCcMO5yDOiLFEyV8y4HDIO0ipg1lk2QPfH3k1oPlqIW12V0YL3poamjZoSQiXBLMMdyo-oDU2MAZzehLIyYa8J1p_OdOdM_3XWxe5OH9q8guIn9C2pA7IjsGv8FkJ89-0Ogl6D8dv1_90H9NF3WA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2112610380</pqid></control><display><type>article</type><title>Gender-Affirming Hormone Therapy for Transgender Females</title><source>Journals@Ovid Complete</source><creator>RANDOLPH, JOHN F</creator><creatorcontrib>RANDOLPH, JOHN F</creatorcontrib><description>The provision of hormone therapy, both estrogens and antiandrogens, to adult transgender females is well within the scope of practice of the obstetrician gynecologist. The goal is to induce feminizing changes and suppress previously developed masculinization. Estrogens in sufficient doses will usually achieve both goals with augmentation by antiandrogens. The primary short-term risk of estrogens is thrombosis, but long-term risk in transgender females is unclear. Optimal care requires pretreatment education and assessment, individualized dosing, ongoing routine monitoring, and standard breast and prostate cancer screening.</description><identifier>ISSN: 0009-9201</identifier><identifier>EISSN: 1532-5520</identifier><identifier>DOI: 10.1097/GRF.0000000000000396</identifier><identifier>PMID: 30256230</identifier><language>eng</language><publisher>United States: Copyright Wolters Kluwer Health, Inc. All rights reserved</publisher><ispartof>Clinical obstetrics and gynecology, 2018-12, Vol.61 (4), p.705-721</ispartof><rights>Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3566-2d159df20f6169d96abea2bf8d648af554a445b819c196b93afbe84e6c9e3cfc3</citedby><cites>FETCH-LOGICAL-c3566-2d159df20f6169d96abea2bf8d648af554a445b819c196b93afbe84e6c9e3cfc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30256230$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>RANDOLPH, JOHN F</creatorcontrib><title>Gender-Affirming Hormone Therapy for Transgender Females</title><title>Clinical obstetrics and gynecology</title><addtitle>Clin Obstet Gynecol</addtitle><description>The provision of hormone therapy, both estrogens and antiandrogens, to adult transgender females is well within the scope of practice of the obstetrician gynecologist. The goal is to induce feminizing changes and suppress previously developed masculinization. Estrogens in sufficient doses will usually achieve both goals with augmentation by antiandrogens. The primary short-term risk of estrogens is thrombosis, but long-term risk in transgender females is unclear. Optimal care requires pretreatment education and assessment, individualized dosing, ongoing routine monitoring, and standard breast and prostate cancer screening.</description><issn>0009-9201</issn><issn>1532-5520</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kE1Lw0AQhhdRbK3-A5EcvaTud7PHUmwrFASp52WzmW2jm6TuNpT--0ZbRTw4l4Hhed-BB6FbgocEq9HD7GU6xL-HKXmG-kQwmgpB8Tnqd0eVKopJD13F-IYx4WJELlGPYSokZbiPshnUBYR07FwZqrJeJfMmVE0NyXINwWz2iWtCsgymjqsvMplCZTzEa3ThjI9wc9oD9Dp9XE7m6eJ59jQZL1LLhJQpLYhQhaPYSSJVoaTJwdDcZYXkmXFCcMO5yDOiLFEyV8y4HDIO0ipg1lk2QPfH3k1oPlqIW12V0YL3poamjZoSQiXBLMMdyo-oDU2MAZzehLIyYa8J1p_OdOdM_3XWxe5OH9q8guIn9C2pA7IjsGv8FkJ89-0Ogl6D8dv1_90H9NF3WA</recordid><startdate>201812</startdate><enddate>201812</enddate><creator>RANDOLPH, JOHN F</creator><general>Copyright Wolters Kluwer Health, Inc. All rights reserved</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201812</creationdate><title>Gender-Affirming Hormone Therapy for Transgender Females</title><author>RANDOLPH, JOHN F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3566-2d159df20f6169d96abea2bf8d648af554a445b819c196b93afbe84e6c9e3cfc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RANDOLPH, JOHN F</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical obstetrics and gynecology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RANDOLPH, JOHN F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gender-Affirming Hormone Therapy for Transgender Females</atitle><jtitle>Clinical obstetrics and gynecology</jtitle><addtitle>Clin Obstet Gynecol</addtitle><date>2018-12</date><risdate>2018</risdate><volume>61</volume><issue>4</issue><spage>705</spage><epage>721</epage><pages>705-721</pages><issn>0009-9201</issn><eissn>1532-5520</eissn><abstract>The provision of hormone therapy, both estrogens and antiandrogens, to adult transgender females is well within the scope of practice of the obstetrician gynecologist. The goal is to induce feminizing changes and suppress previously developed masculinization. Estrogens in sufficient doses will usually achieve both goals with augmentation by antiandrogens. The primary short-term risk of estrogens is thrombosis, but long-term risk in transgender females is unclear. Optimal care requires pretreatment education and assessment, individualized dosing, ongoing routine monitoring, and standard breast and prostate cancer screening.</abstract><cop>United States</cop><pub>Copyright Wolters Kluwer Health, Inc. All rights reserved</pub><pmid>30256230</pmid><doi>10.1097/GRF.0000000000000396</doi><tpages>17</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0009-9201
ispartof Clinical obstetrics and gynecology, 2018-12, Vol.61 (4), p.705-721
issn 0009-9201
1532-5520
language eng
recordid cdi_proquest_miscellaneous_2112610380
source Journals@Ovid Complete
title Gender-Affirming Hormone Therapy for Transgender Females
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T03%3A30%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gender-Affirming%20Hormone%20Therapy%20for%20Transgender%20Females&rft.jtitle=Clinical%20obstetrics%20and%20gynecology&rft.au=RANDOLPH,%20JOHN%20F&rft.date=2018-12&rft.volume=61&rft.issue=4&rft.spage=705&rft.epage=721&rft.pages=705-721&rft.issn=0009-9201&rft.eissn=1532-5520&rft_id=info:doi/10.1097/GRF.0000000000000396&rft_dat=%3Cproquest_cross%3E2112610380%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2112610380&rft_id=info:pmid/30256230&rfr_iscdi=true